TY - JOUR
T1 - Exploring the NCS-382 Scaffold for CaMKII alpha Modulation
T2 - Synthesis, Biochemical Pharmacology, and Biophysical Characterization of Ph-HTBA as a Novel High-Affinity Brain-Penetrant Stabilizer of the CaMKII alpha Hub Domain
AU - Tian, Yongsong
AU - Shehata, Mohamed A.
AU - Gauger, Stine Juul
AU - Veronesi, Carolina
AU - Hamborg, Louise
AU - Thiesen, Louise
AU - Bruus-Jensen, Jesper
AU - Royssen, Johanne Schlieper
AU - Leurs, Ulrike
AU - Larsen, Anne Sofie G.
AU - Krall, Jacob
AU - Solbak, Sara M. O.
AU - Wellendorph, Petrine
AU - Frolund, Bente
PY - 2022
Y1 - 2022
N2 - Ca2+/calmodulin-dependent protein kinase II alpha (CaMKII alpha) is a brain-relevant kinase and an emerging drug target for ischemic stroke and neurodegenerative disorders. Despite reported CaMKII alpha inhibitors, their usefulness is limited by low subtype selectivity and brain permeability. (E)-2-(5-Hydroxy-5,7,8,9-tetrahydro-6H-benzo[7]annulen-6-ylidene)acetic acid (NCS-382) is structurally related to the proposed neuromodulator, gamma-hydroxybutyric acid, and is a brain-penetrating high nanomolar-affinity ligand selective for the CaMKII alpha hub domain. Herein, we report the first series of NCS-382 analogs displaying improved affinity and preserved brain permeability. Specifically, we present Ph-HTBA (1i) with enhanced mid-nanomolar affinity for the CaMKII alpha binding site and a marked hub thermal stabilization effect along with a distinct CaMKII alpha Trp403 flip upon binding. Moreover, Ph-HTBA has good cellular permeability and low microsomal clearance and shows brain permeability after systemic administration to mice, signified by a high Kp, uu value (0.85). Altogether, our study highlights Ph-HTBA as a promising candidate for CaMKII alpha-associated pharmacological interventions and future clinical development.
AB - Ca2+/calmodulin-dependent protein kinase II alpha (CaMKII alpha) is a brain-relevant kinase and an emerging drug target for ischemic stroke and neurodegenerative disorders. Despite reported CaMKII alpha inhibitors, their usefulness is limited by low subtype selectivity and brain permeability. (E)-2-(5-Hydroxy-5,7,8,9-tetrahydro-6H-benzo[7]annulen-6-ylidene)acetic acid (NCS-382) is structurally related to the proposed neuromodulator, gamma-hydroxybutyric acid, and is a brain-penetrating high nanomolar-affinity ligand selective for the CaMKII alpha hub domain. Herein, we report the first series of NCS-382 analogs displaying improved affinity and preserved brain permeability. Specifically, we present Ph-HTBA (1i) with enhanced mid-nanomolar affinity for the CaMKII alpha binding site and a marked hub thermal stabilization effect along with a distinct CaMKII alpha Trp403 flip upon binding. Moreover, Ph-HTBA has good cellular permeability and low microsomal clearance and shows brain permeability after systemic administration to mice, signified by a high Kp, uu value (0.85). Altogether, our study highlights Ph-HTBA as a promising candidate for CaMKII alpha-associated pharmacological interventions and future clinical development.
KW - PROTEIN-KINASE-II
KW - GAMMA-HYDROXYBUTYRIC ACID
KW - GHB LIGANDS DESIGN
KW - ACCURATE DOCKING
KW - SODIUM OXYBATE
KW - BINDING
KW - MECHANISM
KW - RECEPTOR
KW - ANALOGS
KW - GLIDE
U2 - 10.1021/acs.jmedchem.2c00805
DO - 10.1021/acs.jmedchem.2c00805
M3 - Journal article
C2 - 36346645
VL - 65
SP - 15066
EP - 15084
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
SN - 0022-2623
IS - 22
ER -